The Tough Tech problem we are solving
It costs about $1.2 B to develop a new therapeutic drug, largely because 75-80% fail due to efficacy or safety issues associated with ineffective in vivo delivery. This is particularly the case for biologicals such as RNA and protein therapeutics. There is thus an urgent need for developing a) precision drug delivery vehicles for RNA and protein drugs and b) scalable biomanufacturing platforms that can provide sustainable treatment solutions.
About our solution
Accure develops a programmable, biological nano particle (BNP) platform that leverages patients' biomarker profiles and BNP’s natural delivery capabilities to enable precision therapies targeted to the right cells for the right patients. The platform combines advantages of AI protein design, rapid BNP analysis with a GMP-ready, food-based biomanufacturing system, to improve the targeted delivery of RNA and protein therapeutics.